Department of Molecular and Cellular Biology, University of California-Davis, Davis, California, United States; Genome Center, University of California-Davis, Davis, California, United States.
Department of Food Science and Technology, University of California-Davis, Davis, California, United States.
J Nutr Biochem. 2020 May;79:108340. doi: 10.1016/j.jnutbio.2020.108340. Epub 2020 Jan 17.
Human milk oligosaccharides play a vital role in the development of the gut microbiome in the human infant. Although oligosaccharides derived from bovine milk (BMO) differ in content and profile with those derived from human milk (HMO), several oligosaccharide structures are shared between the species. BMO are commercial alternatives to HMO, but their fate in the digestive tract of healthy adult consumers is unknown. Healthy human subjects consumed two BMO doses over 11-day periods each and provided fecal samples. Metatranscriptomics of fecal samples were conducted to determine microbial and host gene expression in response to the supplement. Fecal samples were also analyzed by mass spectrometry to determine levels of undigested BMO. No changes were observed in microbial gene expression across all participants. Repeated sampling enabled subject-specific analyses: four of six participants had minor, yet statistically significant, changes in microbial gene expression. No significant change was observed in the gene expression of host cells exfoliated in stool. Levels of BMO excreted in feces after supplementation were not significantly different from baseline and were not correlated with dosage or expressed microbial enzyme levels. Collectively, these data suggest that BMO are fully fermented in the human gastrointestinal tract upstream of the distal colon. Additionally, the unaltered host transcriptome provides further evidence for the safety of BMO as a dietary supplement or food ingredient. Further research is needed to investigate potential health benefits of this completely fermentable prebiotic that naturally occurs in cow's milk.
人乳寡糖在人类婴儿肠道微生物组的发育中起着至关重要的作用。尽管来源于牛乳的寡糖(BMO)在含量和结构上与来源于人乳的寡糖(HMO)不同,但在这两个物种之间有几种寡糖结构是共有的。BMO 是 HMO 的商业替代品,但它们在健康成年消费者消化道中的命运尚不清楚。健康的人类受试者在 11 天的时间内分别摄入两种 BMO 剂量,并提供粪便样本。对粪便样本进行宏转录组学分析,以确定微生物和宿主基因对补充剂的反应。还通过质谱法分析粪便样本,以确定未消化的 BMO 水平。在所有参与者中,未观察到微生物基因表达的变化。重复采样使能够进行个体特定的分析:六名参与者中有四名的微生物基因表达有轻微但具有统计学意义的变化。在粪便中脱落的宿主细胞的基因表达没有观察到显著变化。补充后粪便中 BMO 的排泄水平与基线相比没有显著差异,也与剂量或表达的微生物酶水平无关。总的来说,这些数据表明 BMO 在人类胃肠道中完全发酵,位于远端结肠的上游。此外,未改变的宿主转录组为 BMO 作为膳食补充剂或食品成分的安全性提供了进一步的证据。需要进一步研究以调查这种天然存在于牛奶中的完全可发酵的益生元的潜在健康益处。